BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200305
DTSTAMP:20260515T060745
CREATED:20191215T130603Z
LAST-MODIFIED:20191215T130603Z
UID:23348-1583193600-1583366399@www.pharmajournalist.com
SUMMARY:Animal Microbiome & Nutritional Health Congress
DESCRIPTION:Building on the huge success of our European Animal Microbiome Congress in London this past July\, we are incredibly excited to return to the USA in March 2020\, this time in Chicago\, Illinois. \n \nInterest in animal microbiomes as therapeutics is rapidly expanding\, as techniques to study the microbial world decrease in cost and increase in accessibility\, and case studies from human medicine receive widespread attention. The current state of techniques and strategies to modify the microbiome to improve animal health\, focusing on applications in domestic pets and farm animals\, will be the main focus of this event. \nWe will be untangling the basic biology of microbiome-directed therapies in animals and the examples to date of application of probiotics\, prebiotics\, and other microbiome-directed therapies and feed additives being used to benefit animal health. We will also be looking heavily at the impact of different feed and nutrition profiles on animal microbiomes\, and the power of nutrition in affecting animal health in a beneficial way. \nFinally\, the event will host the Animal Microbiome & Nutritional Health Innovation Showcase\, where 8 emerging companies in the field of animal nutrition will present the microbiome and nutritional solutions they can bring to market. \nTo learn more about this event and to register online\, visit https://animalmicrobiomecongressusa.com/
URL:https://www.pharmajournalist.com/event/animal-microbiome-nutritional-health-congress/
LOCATION:Warwick Allerton – Chicago\, 701 N Michigan Avenue\, Chicago\, IL\, 60611\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T060745
CREATED:20191215T131423Z
LAST-MODIFIED:20191215T131423Z
UID:23352-1583193600-1583452799@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders
DESCRIPTION:Discover the Clinical & Commercial Potential of Gene Therapy & Editing Approaches Revolutionizing Hemophilia\, Sickle Cell Disease & β-Thalassemia Treatment \nRevolutionary gene therapies are redefining the treatment of blood diseases. \n \nWith an approved gene therapy treatment for β-thalassemia in the EU\, and hemophilia candidates seeking 2020 approval in the USA and beyond\, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia\, sickle cell disease and\nβ-thalassemia. \nEvaluate the best strategies for a commercial launch in blood disease\, optimize your trial design\, gain insights on revolutionary novel technologies\, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently. \nDownload the full event guide to learn more from companies including bluebird bio\, Spark Therapeutics and Editas Medicine
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200304
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T060745
CREATED:20200217T092857Z
LAST-MODIFIED:20200217T093049Z
UID:24197-1583280000-1583452799@www.pharmajournalist.com
SUMMARY:8th Annual Pharma AntiCounterfeiting & Serialisation 2020
DESCRIPTION:8th Annual Pharma AntiCounterfeiting & Serialisation 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI\, IoT and blockchain within pharma and healthcare through a mixture of practical\, lectures and roundtable discussions specifically designed. \nCONFERENCE SPONSORS: \n\nIO AG\n\nWe have sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in \nCONFERENCE DELEGATE PRICING: \nIn order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in \nPlease note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event. \n \nEarly Bird Discount Price: \n1 Delegate @ £899 + VAT (Valid Till 24th Jan 2020) \n3 Delegates @ £1798 + VAT (Valid Till 25th Jan 2020) \nStandard Price: \n1 Delegate @ £1299 + VAT (Valid from 25th Jan 2020) \n3 Delegates @ £2598 + VAT (Valid from 25th Jan 2020) \nKEY SPEAKERS: \n\nNICHOLAS CALL\, Special Agent\, FDA\nGALIT MEYRAN\, Serialization Global Program Manager\, Teva\nMARCEL DE GRUTTER \, Project Manager Serialization – Regulatory & Government Affairs Liaison\, Abbott\nPATRIK MERCKELL\, External Business Process Analyst and Project Manager\, Roche\nEIKE HILLBRICHT \, Corporate Security Manager\, Boehringer Ingelheim\nJACK JING \, Global Business Development Director / Head of EU Commercial Operations\, Seacross Pharmaceuticals\nLEYLA HANNBECK \, CEO\, Association of Independent Multiple Pharmacies\nSULTAN DAJANI \, Pharmacist Superintendent\, Wainwrights Chemists\nTRACQ ANTOINE\, Head of Commercial Logistics & Serialization\, Galderma\nADRIAN VAN DEN HOVEN\, Director General of Medicines for Europe\, European Medicines Verification Organisation (EMVO)\nMIKE ISLES\, Executive Director\, European Alliance for Access to Safe Medicines\nMONIKA DERECQUE POIS\, Director General\, GIRP—European Healthcare Distribution Association\nBILL ARONSON \, COO\, Artificial Intelligence Research Group\nMARIE MANLEY \, Partner\, Head of the UK Life Sciences Practice\, Sidley Austin\nSANDY EISEN\, Chief Medical Officer\, Fromtline Pharma\n\nPlus many more \nKEY THEMES: \nAnti-counterfeiting\, Serialisation\, T&T \n\nShaping the future for Healthcare\nEffect of Post (FMD) Deadline\nSerialisation strategies- Choosing a Serialisation solution\nAI algorithms to crack down on fake products\nFight the FAKE – Protect the public\nTechnology Impact – Current digital world\nSerialisation and Compliance\nPenetrating the legitimate supply chain\nPackaging Techniques – Protecting your products\n\nBrexit \n\nImpact on EU\, US and Row market\n\nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/8th-annual-pharma-anticounterfeiting-serialisation-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200304
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T060745
CREATED:20200217T093608Z
LAST-MODIFIED:20200217T093608Z
UID:24207-1583280000-1583452799@www.pharmajournalist.com
SUMMARY:3rd Annual Phrama AI\, IoT & Blockchain 2020
DESCRIPTION:“Competences to Combat Counterfeits & Impact of AI\, IoT\, Blockchain & Big Data in Pharma” \nOur 3rd Annual Pharma AI\, IoT & Blockchain 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI\, IoT and blockchain within pharma and healthcare through a mixture of practical\, lectures and roundtable discussions specifically designed. \nSPONSORS: \n\nio AG\nAdvanco\n\nWe have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in \n \nCONFERENCE DELEGATE PRICING: \nPlease note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event. \nIn order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nKEY SPEAKERS: \n\nSTEVEN ABRAHAMSON\, Senior Director\, Product Cyber Security\, GE Healthcare\nPATRIC JARCHOW \, Head of Global Multi-Channel Strategy\, Merck KGaA\nNICLAS NILSSON \, Head of Open Innovation in Research\, LEO Pharma\nSTEVEN WILLIAMSON\, Audit Account Director\, Information Security\, GSK\nEDDIE GUZDAR \, Medical Head UK & Ireland | Physician | Venture Capital & Board Advisor – Digital Technology\, Sanofi Genzyme\nNATALIA M.MONTEIRO\, Clinical Trial Budget & Metrics Management\, Takeda Pharmaceuticals\nPINGPING NI\, Director\, Biometrics Team Lead\, AstraZeneca\nALAN HOW\, Strategy & Operations – Global Commercial\, Merck\nHUSSAIN AL MUSCATI \, Customer Engineering Lead\, Life Sciences\, Google\nMARCO GUIDOBALDI \, Sales Engineer – Healthcare & Life Sciences\, Google\nEBERHARD SCHEUER \, Chairman\, HIT Foundation\nGABOR PURMAN \, Senior Account Director\, Patient Services and Medical Education\, NexGen Healthcare Communications\nROMIKA BHOWMICK\, Senior Manager – Digital Commercial (Europe & International Markets)\, Teva\nBRAM VAN LEEUWEN \, Lead (digital) Innovation BeNeLux\, Sanofi\nEVI MATHIOU\, Legal\, Compliance & Quality Manager BA Europe East & South\, Novo Nordisk\nMYLES FURNACE\, Digital Health and Data Lead\, UK & Ireland Speciality Care\, IPSEN\nRAMESH KRISHNAMURTHY \, Strengthen international institutions\, WHO (World Health Organization)\nSIDDHI TRIVEDI \, Healthcare Innovator\, Co-founder\, Beyond Identity \nALF GOEBEL\, CEO\, Advanco\nIGNACIO H. MEDRANO\, Founder & Chief Medical Officer\, SAVANA\nEDITH LECOMTE NORRANT \, CEO & CSO\, IPSOMEDIC\nROBIN SMITH\, Security and Information Assurance Lead\, Independent Office for Police Conduct (IOPC)\n\nPlus many more \nKEY THEMES: \nAI and IoT \n\nApplications in Pharma and Healthcare\nChallenges and opportunities\nUse of AI in drug discovery\nRole of Cyber Security in age of IoT and Healthcare Hacks\nIP – Cybercrime in the pharmaceutical industry: a booming business\nTransforming the healthcare and pharmaceutical industry\n\nBlockchain \n\nHow it transforms pharma and healthcare\nBlockchain in Logistics and Supply Chain\nA must learn technology\nBlockchain technology and start-ups – where do you get started?\nApplication areas for blockchain within healthcare?\n\nBig Data \n\nPotential future in synchronicity of data\nBig data =Big impact\nA Revolution in Drug Discovery and Pharma R&D\nHow to involve patients better to develop drugs\n\nBrexit \n\nImpact on EU\, US and Row market\n\nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/3rd-annual-phrama-ai-iot-blockchain-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200310
DTEND;VALUE=DATE:20200313
DTSTAMP:20260515T060745
CREATED:20191218T094051Z
LAST-MODIFIED:20191218T094051Z
UID:23467-1583798400-1584057599@www.pharmajournalist.com
SUMMARY:Inborn Errors of Metabolism Drug Development
DESCRIPTION:Join over 80 inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. The inaugural Inborn Errors of Metabolism Drug Development Summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases. \nWith scarce treatment options leaving inborn errors of metabolism a devastating\, unfilled and unmet medical need\, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time\, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy\, safety and commercial viability. \nIncorporating insights from industry-leading speakers\, this conference will delve into the key patient access\, regulatory\, clinical and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfil their full commercial potential. \nThis is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism. \nTo know more about Inborn Errors of Metabolism Drug Development please click here.
URL:https://www.pharmajournalist.com/event/inborn-errors-of-metabolism-drug-development/
LOCATION:Courtyard Boston Downtown/North Station\, 107 Beverly Street\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200312
DTEND;VALUE=DATE:20200314
DTSTAMP:20260515T060745
CREATED:20191031T101142Z
LAST-MODIFIED:20191031T104348Z
UID:23118-1583971200-1584143999@www.pharmajournalist.com
SUMMARY:4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
DESCRIPTION:In the past decade\, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies\, cancer vaccines\, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction. \n \nOur 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London\, UK would address the challenges and future directions in IO research. The congress aims to bring academicians\, researchers and scientists from research institutes pharmaceutical\, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s\, Bispecific Antibodies\, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies\, pre-clinical and translational immune-oncology developments\, updates in cellular and viral therapies\, vaccines development and personalized immunotherapy. Keynote presentations\, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. \nKey Sessions: \n\nUpdates in development of monoclonal antibodies\, ADC’s and Bispecific Ab’s\nImmune Checkpoint Inhibitors and Combinations\nPreclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)\nBiomarkers and Cancer Vaccines\nCAR-T cell therapy\, T Cell Therapy\nTumor microenvironment\nOncolytic Viruses\nMicrobiome in Cancer Immunotherapy\n\nTo learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here \n 
URL:https://www.pharmajournalist.com/event/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/
LOCATION:ILEC Conference Center and IBIS London Earls Court\, 47 Lillie Road\, London\, SW6 1UD
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:shardul.oza@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200316
DTEND;VALUE=DATE:20200318
DTSTAMP:20260515T060745
CREATED:20191101T085034Z
LAST-MODIFIED:20191101T085034Z
UID:23143-1584316800-1584489599@www.pharmajournalist.com
SUMMARY:AI in Drug Discovery Conference 2020
DESCRIPTION:Leveraging machine learning – discovery to the next level! \nSMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020. \nAI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR\, AI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nThe presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning\, neural networks and natural language processing. However\, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms. \n \nBENEFITS OF ATTENDING: \n\nListen to case studies form industry leader pharmaceutical and biotechnology that have already incorporated AI into their work\nExplore how Deep Learning Methods can be leveraged for compound screening\, de novo design\, multiparameter optimization/ ADME toxicity property predictions\, chemical synthesis route predictions\nDiscover strategies for overcoming data-related challenges such as lack of consistent and quality data at the heart of AI and strategies for improving data access\nDefine unique discovery approaches such as fragment-based drug discovery and network-driven drug discovery\n\nJoin us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening\, multi parameter optimization\, disease modelling\, drug synthesis and design. \nTo register please visit: www.AI-indrugdiscovery.com/pharmajwl \nPLUS\, one interactive half-day post-conference workshop \nPractical application of predictive properties in drug design\, Workshop Leader: Robert Young\, Blue Burgundy Ltd. \nEarly-Bird Rates \n\nBOOK BY 29TH NOVEMBER AND SAVE £400\nBOOK BY 13TH DECEMBER AND SAVE £200\nBOOK BY 31ST JANUARY AND SAVE £100\n\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiDrugdiscovery\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/ai-in-drug-discovery-conference-2020/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200317
DTEND;VALUE=DATE:20200319
DTSTAMP:20260515T060745
CREATED:20191215T125706Z
LAST-MODIFIED:20191215T125706Z
UID:23344-1584403200-1584575999@www.pharmajournalist.com
SUMMARY:Formulation & Delivery Series US
DESCRIPTION:Join over 250 leaders\, experts and researchers at the Formulation & Drug Delivery US Series\, connecting global pharma\, biotech and academia for high-level discussions on the latest innovations for biopharmaceutical development. \n \nThe Formulation & Drug Delivery Congress will discuss the state of the industry\, looking at new strategies for optimizing biologic formulations such as antibodies\, proteins and vaccines\, as well as highlighting key updates in amorphous solid dispersions and combination products. \nAlongside this\, The Inhalation & Respiratory Drug Delivery Congress will examine the latest developments in inhaled vaccines and antibiotics\, alongside challenges and trends in generic formulation. \nFeaturing over 55+ renowned industry speakers from leading organisations such as Merck\, Takeda and AstraZeneca\, this programme will allow you to discuss the key topics that interest you. \nView the Programme: https://bit.ly/33nCbI2 \n 2020 Live Webinars: \n‘The Design And Development Of A Connected Inhalation System To Help With Monitoring And Patient Adherence’ – Hosted by Paul Upham\, Head\, Smart Devices\, Genentech  \n“Understanding Supersaturation Of Small Molecule To Improve Oral Bioavailability”  – Hosted by Sudhakar Garad\, Global Head of Chemical and Pharmaceutical Profiling\, Novartis Institutes for BioMedical Research \n“Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development” – Hosted by Hovik Gukasyan\, Associate Director\, Early Development Formulation and Physical Chemistry\, Allergan \nWebinar Registration:  https://bit.ly/2qvy91O \nGo Social: For the latest conference updates follow us on Twitter @FDDCongress and join the congress conversation on #FDDUS20  \nFor more information about the event\, please contact Guillaume Alonso at g.alonso@oxfordglobal.co.uk
URL:https://www.pharmajournalist.com/event/formulation-delivery-series-us/
LOCATION:Hilton San Diego Mission Valley\, 901 Camino del Rio South\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Oxford Global":MAILTO:g.alonso@oxfordglobal.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200403
DTSTAMP:20260515T060745
CREATED:20191104T104106Z
LAST-MODIFIED:20191104T121228Z
UID:23228-1585526400-1585871999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith approvals in a number of indications over the last year\, and more rapidly approaching on the horizon\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies\ndrug developers are employing to improve efficacy\, safety and commercial viability. \nIncorporating insights from 80+ industry-leading speakers\, this conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 600+ of your colleagues to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward in 2020. \nTo know more about 4th Annual Gene Therapy for Rare Disorders click here.
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200402
DTSTAMP:20260515T060745
CREATED:20191215T132020Z
LAST-MODIFIED:20191215T132020Z
UID:23357-1585526400-1585785599@www.pharmajournalist.com
SUMMARY:Cell Engager Summit
DESCRIPTION:The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \n \nUnderstand the very latest in construct design\, immune cell biology\, tumor associated activation\, toxicity assessment\, solid tumor targeting strategies\, clinical insights and more. \nDiscover how to effectively scale complicated manufacturing of multi-specific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies. \nWith 22+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders\, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges. \nTo learn more about this event and to register online\, visit https://ter.li/hkw9b8
URL:https://www.pharmajournalist.com/event/cell-engager-summit-2020/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200401
DTSTAMP:20260515T060745
CREATED:20191215T210012Z
LAST-MODIFIED:20200323T125422Z
UID:23453-1585526400-1585699199@www.pharmajournalist.com
SUMMARY:SMi’s 22nd Annual Superbugs & Superdrugs Conference
DESCRIPTION:A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance \nSponsored by Scynexis \nCO-CHAIRS FOR 2020: Cara Cassino\, Chief Medical Officer\, Contrafect and Michael Dawson\, Director\, Mike Dawson Antimicrobial Research Consultancy \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.superbugssuperdrugs.com \nAs one of the most impactful pharmaceuticals for maintaining public health\, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal\, including colistin\, carbapenems\, 3rd and 4th generation cephalosporins\, useless. \n \nThis year’s event aims to showcase a suite of sessions focused on novel drugs and approaches\, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. \nIt is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR\, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR\, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020\, along with leaders from the pharmaceutical industry\, academia\, regulatory and funding bodies\, and public-private partnerships to discuss the way forward. #SMiBugs \nFEATURED SPEAKERS FOR 2020: \n\nYuri Gleba\, Professor\, Founder\, Nomad Bioscience\nMark Albrecht\, Branch Chief\, Antibacterials program\, BARDA/HHS\nPaul Finn\, CEO\, Oxford Drug Design\nCara Cassino\, Chief Medical Officer\, Contrafect\nMartin Everett\, CSO\, Antabio\nSamareh Lajaunias\, Director\, Combioxin SA\nFrancois Moreau\, Scientific Director\, Mutabilis\nEmma Leire\, Microbiology Lead\, Centauri Therapeutics\nLorenzo Corsini\, Co-Founder/CEO/R&D\, Phagomed\nStephen Barat\, VP\, Preclinical Research and Early Development\, Scynexis\nColm Leonard\, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro \n\nWHATS ON THE AGENDA FOR 2020? \n\nDiscuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience\nGain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin\nExamine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust\nExplore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect\nEvaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design\n\nTo register visit www.superbugssuperdrugs.com/PJWL \nEARLY BIRD-RATES \n\nREGISTER BY 29TH NOVEMBER AND SAVE £400http://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/Holiday Inn Kensington ForumHoliday Inn Kensington Forum\nREGISTER BY 13TH DECEMBER AND SAVE £200\nREGISTER BY 31ST JANUARY AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Rd Kensington\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR